[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640247":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":40,"collaborators":44,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":19,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":19,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":68,"whyStopped":19,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LVIVO-TaVec122 product","EXPERIMENTAL","Each subject will be given a single-dose LVIVO-TaVec122 product infusion at each dose level.",[13],"Biological: LVIVO-TaVec122 product",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Prior to infusion of the LVIVO-TaVec122 product, subjects will receive bridging therapy if needed.",[9],null,[21],{"facility":5,"status":19,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Nanjing","Jiangsu","210029","China","CN",{"type":28,"coordinates":29},"Point",[30,31],118.77778,32.06167,{"lat":31,"lon":30},[34],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Lei Fan, Doctor","CONTACT","13813976136","+186","fanlei3014@126.com",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Lei Fan","Director of lymphoma center",[45],{"name":46,"class":47},"Nanjing Legend Biotech Co.","INDUSTRY","100640247","phase-1-a-study-of-the-lvivo-tavec122-product-in-subjects-with-relapsedrefractory-b-cell-malignancies-100640247",false,"NCT07628582","A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed\u002FRefractory B-cell Malignancies","An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the LVIVO-TaVec122 Product in Subjects With Relapsed\u002FRefractory B-cell Malignancies","Inclusion Criteria:\n\n1. Subjects voluntary agreement to provide written informed consent.\n2. Age ≥ 18 years.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. At least one evaluable tumor lesion.\n5. Relapsed and\u002For refractory Non-Hodgkin Lymphoma (NHL) , and relapsed and\u002For refractory Chronic Lymphocytic Leukemia (CLL) with treatment indications.\n6. Clinical laboratory values meet screening visit criteria.\n7. Adequate organ function.\n\nExclusion Criteria:\n\n1. Prior antitumor therapy with insufficient washout period.\n2. Prior treatment with allo-Hematopoietic stem cell transplantation (HSCT) or gene therapies.\n3. Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab).\n4. Known life-threatening allergic reaction, hypersensitivity reaction, or intolerance to study drug excipients and related excipients, including but not limited to Human Albumin, or those with a history of severe allergic reactions in the past (such as hypersensitivity reactions, or those with severe immune-related reactions such as the need for glucocorticoids to prevent anaphylaxis as assessed by the investigator).\n5. Female subjects who were pregnant, breastfeeding.\n6. Any condition deemed by the investigator as rendering the subject unsuitable for participation in this study.","ALL","18 Years",{"count":58,"type":59},48,"ESTIMATED","INTERVENTIONAL",[62],"PHASE1","This is a single-arm, open-label and dose-escalation clinical study to evaluate the LVIVO-TaVec122 product in adult subjects with Relapsed\u002FRefractory B-cell Malignancies.",[65],"Relapsed\u002FRefractory B-cell Malignancies",[67],"B-cell malignancies","NOT_YET_RECRUITING","2026-06-04",{"date":71,"type":72},"2026-06-05","ACTUAL",{"date":74,"type":59},"2026-09-15",{"date":76,"type":59},"2030-09-30",{"name":5,"class":6},1]